Clinical Images: Hidden in plain sight: a case of tattoo-associated sarcoidosis
ACR Open Rheumatol. 2025 Dec;7(12):e70129. doi: 10.1002/acr2.70129. NO ABSTRACT PMID:41457039 | DOI:10.1002/acr2.70129
ACR Open Rheumatol. 2025 Dec;7(12):e70129. doi: 10.1002/acr2.70129. NO ABSTRACT PMID:41457039 | DOI:10.1002/acr2.70129
Joint Bone Spine. 2025 Dec 26:106029. doi: 10.1016/j.jbspin.2025.106029. Online ahead of print. ABSTRACT OBJECTIVES: Despite the importance of activity for
Pain Manag Nurs. 2025 Dec 27:S1524-9042(25)00350-9. doi: 10.1016/j.pmn.2025.12.009. Online ahead of print. ABSTRACT PURPOSE: High levels of stigma among patients
Joint Bone Spine. 2025 Dec 26:106028. doi: 10.1016/j.jbspin.2025.106028. Online ahead of print. ABSTRACT Musculoskeletal manifestations of transthyretin amyloidosis (ATTR) are
Joint Bone Spine. 2025 Dec 26:106027. doi: 10.1016/j.jbspin.2025.106027. Online ahead of print. ABSTRACT This was a young female patient admitted
J Allergy Clin Immunol. 2025 Dec 26:S0091-6749(25)02188-8. doi: 10.1016/j.jaci.2025.12.991. Online ahead of print. ABSTRACT BACKGROUND: Adaptive immune responses are tightly
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with
Objective Cellular mechanisms driving transition from psoriasis to psoriatic arthritis have remained largely elusive. Thus, we investigated changes within the
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood-onset systemic lupus erythematosus (cSLE) remain unclear.
Arthritis &Rheumatology, EarlyView.
Clin Exp Med. 2025 Dec 28. doi: 10.1007/s10238-025-02014-1. Online ahead of print. ABSTRACT Systemic Lupus Erythematosus (SLE) is an autoimmune
Reflecting these concerns, the 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations emphasize minimizing GC use whenever …
Hereditas. 2025 Dec 28. doi: 10.1186/s41065-025-00631-0. Online ahead of print. ABSTRACT BACKGROUND: Ubiquitination-related genes (UbRGs) play critical roles in tumor
Clin Rheumatol. 2025 Dec 28. doi: 10.1007/s10067-025-07746-9. Online ahead of print. ABSTRACT BACKGROUND: Patient education materials are vital to health
Int J Rheum Dis. 2026 Jan;29(1):e70528. doi: 10.1111/1756-185x.70528. NO ABSTRACT PMID:41455607 | DOI:10.1111/1756-185x.70528
Sci Rep. 2025 Dec 27. doi: 10.1038/s41598-025-34071-7. Online ahead of print. NO ABSTRACT PMID:41455752 | DOI:10.1038/s41598-025-34071-7
Int J Rheum Dis. 2026 Jan;29(1):e70534. doi: 10.1111/1756-185x.70534. NO ABSTRACT PMID:41455606 | DOI:10.1111/1756-185x.70534
Int J Cardiol. 2025 Dec 25:134119. doi: 10.1016/j.ijcard.2025.134119. Online ahead of print. ABSTRACT INTRODUCTION: Myocarditis is a severe condition characterized
Med. 2025 Dec 26:100934. doi: 10.1016/j.medj.2025.100934. Online ahead of print. ABSTRACT BACKGROUND: Coagulation factor XI (FXI) influences both thrombotic risk
J Nutr Health Aging. 2025 Dec 26;30(1):100767. doi: 10.1016/j.jnha.2025.100767. Online ahead of print. NO ABSTRACT PMID:41455464 | DOI:10.1016/j.jnha.2025.100767
Respir Investig. 2025 Dec 26;64(1):101358. doi: 10.1016/j.resinv.2025.101358. Online ahead of print. ABSTRACT BACKGROUND: Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a
Semin Arthritis Rheum. 2025 Dec 22;76:152901. doi: 10.1016/j.semarthrit.2025.152901. Online ahead of print. ABSTRACT OBJECTIVES: to investigate the impact of cutaneous,
Cytokine. 2025 Dec 26;198:157103. doi: 10.1016/j.cyto.2025.157103. Online ahead of print. ABSTRACT BACKGROUND: The dynamics of peripheral immune cells during the
Cell Rep. 2025 Dec 26;45(1):116775. doi: 10.1016/j.celrep.2025.116775. Online ahead of print. ABSTRACT Lupus nephritis (LN) is a leading cause of
Rheumatol Ther. 2025 Dec 27. doi: 10.1007/s40744-025-00818-x. Online ahead of print. ABSTRACT INTRODUCTION: Psoriatic arthritis (PsA) is a heterogeneous, progressive
Lupus. 2025 Dec 27:9612033251413980. doi: 10.1177/09612033251413980. Online ahead of print. ABSTRACT ObjectiveTo evaluate whether hydroxychloroquine (HCQ) dose reduction (2-3 mg/kg/day)
Rheumatol Int. 2025 Dec 27;46(1):25. doi: 10.1007/s00296-025-06066-0. NO ABSTRACT PMID:41454972 | DOI:10.1007/s00296-025-06066-0